Humanized antibodies that recognize alpha-synuclein
US-9217030-B2 · Dec 22, 2015 · US
US9468693B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9468693-B2 |
| Application number | US-201414161863-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 23, 2014 |
| Priority date | Jan 23, 2014 |
| Publication date | Oct 18, 2016 |
| Grant date | Oct 18, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Imaging agents are described that comprise labeled substrates capable of being introduced into cells via the cystine/glutamate antiporter. The substrates may be used for imaging or detecting oxidative stress in cells by introducing the labeled agents into cells via the cystine/glutamate antiporter and subsequent detection.
Opening claim text (preview).
The invention claimed is: 1. An imaging agent comprising a compound of Formula I wherein X is 18 F, 3 H, —(CH 2 ) m Z, —CH 2 —O—(CH 2 ) m Z, or —O—(CH 2 ) m Z; Z is 18 F or 3 H; m is an integer between 1 and 5; Y is O—CH 2 , CH 2 —O, CH 2 —CH 2 , CH 2 —CH 2 —CH 2 , O—CH 2 —CH 2 , or CH 2 —O—CH 2 ; and Ar is a 3-substituted phenyl, 4-substituted phenyl, 4-substituted naphthalene-1-yl, 5-substituted naphthalene-1-yl, or 6-substituted naphthalene-2-yl. 2. The agent of claim 1 wherein X is —O—(CH 2 ) m Z. 3. The agent of claim 2 wherein Z is 18 F or 3 H. 4. The agent of claim 3 wherein Z is a singularly occurring 18 F. 5. The agent of claim 1 wherein Formula I is 6. The agent of claim 1 wherein Formula I is 7. The agent of claim 1 wherein Formula I is
Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions · CPC title
for testing the pathological state of an organism · CPC title
having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil · CPC title
Heterocyclic compounds · CPC title
Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.